{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:34:58Z","timestamp":1761863698134,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40121-017-0158-x","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T07:00:51Z","timestamp":1493967651000},"page":"265-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study"],"prefix":"10.1007","volume":"6","author":[{"given":"Geert","family":"Robaeys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Lucidarme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Arain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Bruggmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Kunkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Keim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"J\u00e4kel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"DeMasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lonjon-Domanec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,5]]},"reference":[{"unstructured":"WHO hepatitis C fact sheet. Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/ . Accessed 7 Feb 2017.","key":"158_CR1"},{"issue":"Suppl. 1","key":"158_CR2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","volume":"21","author":"H Razavi","year":"2014","unstructured":"Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm. J Viral Hepat. 2014;21(Suppl. 1):34\u201359.","journal-title":"J Viral Hepat."},{"issue":"Suppl 1","key":"158_CR3","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","volume":"65","author":"H Midgard","year":"2016","unstructured":"Midgard H, Weir A, Palmateer N, Lo Re V 3rd, Pineda JA, Mac\u00edas J, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65(Suppl 1):S33\u201345.","journal-title":"J Hepatol"},{"issue":"10","key":"158_CR4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmi.2016.07.035","volume":"22","author":"S Lanini","year":"2016","unstructured":"Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global\u00a0epidemiology\u00a0and strategies for control. Clin Microbiol Infect. 2016;22(10):833\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"158_CR5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.28227","volume":"63","author":"A Cousien","year":"2016","unstructured":"Cousien A. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology. 2016;63:1090\u2013101.","journal-title":"Hepatology"},{"issue":"Suppl. 5","key":"158_CR6","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1086\/427441","volume":"40","author":"BR Edlin","year":"2005","unstructured":"Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005;40(Suppl. 5):S276\u201385.","journal-title":"Clin Infect Dis"},{"key":"158_CR7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00042737-200602000-00008","volume":"18","author":"G Robaeys","year":"2006","unstructured":"Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F, et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006;18:159\u201366.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"158_CR8","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/MEG.0b013e328338d9aa","volume":"22","author":"P Melin","year":"2010","unstructured":"Melin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Lang JP, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22:1050\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"158_CR9","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchinson JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C infection. N Engl J Med. 2011;364:2405\u201316.","journal-title":"N Engl J Med"},{"key":"158_CR10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207\u201317.","journal-title":"N Engl J Med"},{"key":"158_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41124-016-0011-y","volume":"1","author":"JF Dillon","year":"2016","unstructured":"Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Pol. 2016;1:2.","journal-title":"Hepatol Med Pol."},{"key":"158_CR12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","volume":"165","author":"GJ Dore","year":"2016","unstructured":"Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir-grazoprevir to treat Hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165:625\u201334.","journal-title":"Ann Intern Med"},{"key":"158_CR13","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","volume":"47","author":"ZD Goodman","year":"2007","unstructured":"Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47:598\u2013607.","journal-title":"J Hepatol"},{"key":"158_CR14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.24013","volume":"53","author":"SM Martinez","year":"2011","unstructured":"Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325\u201335.","journal-title":"Hepatology"},{"key":"158_CR15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00002030-200201250-00017","volume":"16","author":"JC Walsh","year":"2002","unstructured":"Walsh JC, Mandalia S, Gazzard BG. Responses to a 1\u00a0month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16:269\u201377.","journal-title":"AIDS."},{"key":"158_CR16","volume-title":"AUDIT: The alcohol use disorders identification test, guidelines for use in primary care","author":"TF Babor","year":"2001","unstructured":"Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT: The alcohol use disorders identification test, guidelines for use in primary care. Geneva: World Health Organization. Department of Mental Health and Substance Dependence; 2001."},{"key":"158_CR17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","volume":"88","author":"JB Saunders","year":"1993","unstructured":"Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption II. Addiction. 1993;88:791\u2013804.","journal-title":"Addiction"},{"key":"158_CR18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/apt.13095","volume":"41","author":"RK Sterling","year":"2015","unstructured":"Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, et al. Virologic outcomes and treatment algorithms utilization in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Aliment Pharmacol Ther. 2015;41:671\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"158_CR19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw579","volume":"63","author":"J Grebely","year":"2016","unstructured":"Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, et al. Efficacy and safety of sofosbuvir\/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of Phase 3 ASTRAL results. Clin Infect Dis. 2016;63:1479\u201381.","journal-title":"Clin Infect Dis"},{"key":"158_CR20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/cid\/ciw580","volume":"63","author":"J Grebely","year":"2016","unstructured":"Grebely J, Mauss S, Brown A, Bronowicki J-P, Puoti M, Wyles D, et al. Efficacy and safety of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic HCV Genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. Clin Infect Dis. 2016;63:1405\u201311.","journal-title":"Clin Infect Dis"},{"unstructured":"Christensen S, Schober A, Mauss S, Busch H, G\u00fcnther R, Teuber G, et al. DAA-treatment of HCV-infected patients on Opioid Substitution Therapy (OST): does the clinical setting matter? Data from the German Hepatitis C-Registry (DHC-R). AASLD Liver Meeting 2016. Boston, MA, November 11\u201315 2016. Abstract 1980.","key":"158_CR21"},{"unstructured":"Hull M, Gallagher L, Pare D, Kason D, Persaud S, Nouch S, et al. Real world outcomes of direct acting antiviral (DAA) therapy for hepatitis C (HCV) amongst persons who inject drugs treated in an inner-city hepatitis C treatment program, Vancouver, Canada. 2016. 5th International Symposium on Hepatitis Care in Substance Users. Available at: https:\/\/www.eiseverywhere.com\/file_uploads\/1a0a6aab975530ed73e635f394654af3_139_MarkHull.pdf . Accessed 7 Feb 2017.","key":"158_CR22"},{"key":"158_CR23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2217\/fvl-2016-0042","volume":"11","author":"A Alimohammadi","year":"2016","unstructured":"Alimohammadi A, Hakobyan S, Raycraft T, Vafadary S, Conway B. Evaluation of HCV treatment in people who actively inject drugs. Fut Virol. 2016;11:483\u20137.","journal-title":"Fut Virol."},{"unstructured":"Litwin AH, Agyemang L, Akiyama M, Heo M, Wong J, Soloway IJ, et al. High rates of sustained virological response in people who inject drugs treated with all-oral direct acting antiviral regimens. 5th International Symposium on Hepatitis Care in Substance Users. Available at: https:\/\/www.eiseverywhere.com\/file_uploads\/ec626d74ab97207d900ddc93eeb18144_166_AlainLitwin.pdf . Accessed 7 Feb 2017.","key":"158_CR24"},{"doi-asserted-by":"crossref","unstructured":"Bielen R, Van Vlierberghe H, Bourgeois S, Moreno C, Vanwollegem T, Verlinden W, Mulkay JP, et al. Belgian experience with direct acting antivirals in people who inject drugs. AASLD 2016:Abstract 910.","key":"158_CR25","DOI":"10.1016\/j.drugalcdep.2017.04.003"},{"key":"158_CR26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsat.2017.01.015","volume":"75","author":"BL Norton","year":"2017","unstructured":"Norton BL, Beitin A, Glenn M, DeLuca J, Litwin AH, Cunningham CO. Retention in buprenorphine treatment is associated with improved HCV care outcomes. J Subst Abuse Treat. 2017;75:38\u201342.","journal-title":"J Subst Abuse Treat"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-017-0158-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T07:54:49Z","timestamp":1569225289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-017-0158-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,5]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["158"],"URL":"https:\/\/doi.org\/10.1007\/s40121-017-0158-x","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2017,5,5]]}}}